...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Human Kallikrein 13: Production and Purification of Recombinant Protein and Monoclonal and Polyclonal Antibodies, and Development of a Sensitive and Specific Immunofluorometric Assay
【24h】

Human Kallikrein 13: Production and Purification of Recombinant Protein and Monoclonal and Polyclonal Antibodies, and Development of a Sensitive and Specific Immunofluorometric Assay

机译:人类激肽释放酶13:重组蛋白,单克隆和多克隆抗体的生产和纯化,以及敏感性和特异性免疫荧光测定法的发展

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: The aims of this study were to develop immunologic reagents and a sensitive and specific immunoassay for human kallikrein 13 (hK13) and to examine the presence of hK13 in human tissues and biological fluids.Methods: Recombinant hK13 protein was produced and purified with use of a Pichia pastoris yeast expression system. The protein was used as an immunogen to generate mouse monoclonal and rabbit polyclonal anti-hK13 antibodies. A sandwich-type immunoassay was developed with these antibodies. The assay was used to measure hK13 in various biological fluids and tissue extracts. Immunohistochemical analysis was also performed on nondiseased and cancerous prostatic sections.Results: The hK13 immunoassay had a detection limit of 0.05 μg/L and showed no cross-reactivity with homologous kallikreins. The assay was linear at 0–20 μg/L, and within-and between-run CVs were 10% (n = 12). hK13 was detected in tissues, including esophagus, tonsil, trachea, lung, cervix, and prostate. hK13 was also found in seminal plasma, amniotic fluid, follicular fluid, ascites of ovarian cancer patients, breast milk, and cytosolic extracts of ovarian cancer tissues. hK13 was immunohistochemically localized in epithelial cells of both nondiseased and cancerous prostate. hK13 appears to be overexpressed in 50% of ovarian cancer tissues compared with healthy ovarian tissues. Recovery of active enzyme added to milk or amniotic fluid was 70–98%, but was 20% when added to serum, suggesting rapid sequestration by protease inhibitors. In fluids and tissue extracts, hK13 was found in its free (~30 kDa) form.Conclusions: This immunofluorometric assay for hK13 may be used to examine the value of hK13 as a disease biomarker and to further explore the physiologic and pathobiologic role of this enzyme in human disease.
机译:背景:这项研究的目的是开发针对人类激肽释放酶13(hK13)的免疫试剂和灵敏且特异性的免疫分析方法,并检测人类组织和生物体液中hK13的存在。方法:重组hK13蛋白的制备和纯化毕赤酵母酵母表达系统的构建。该蛋白被用作免疫原,以产生小鼠单克隆和兔多克隆抗hK13抗体。用这些抗体开发了夹心型免疫测定法。该测定法用于测量各种生物流体和组织提取物中的hK13。结果:hK13免疫分析的检出限为0.05μg/ L,与激肽释放酶没有交叉反应。该测定法在0–20μg/ L时呈线性,运行中和运行中CV均<10%(n = 12)。在包括食道,扁桃体,气管,肺,子宫颈和前列腺的组织中检测到hK13。在精浆,羊水,卵泡液,卵巢癌患者腹水,母乳和卵巢癌组织的胞浆提取物中也发现了hK13。 hK13免疫组织化学定位在未患病和癌性前列腺的上皮细胞中。与健康的卵巢组织相比,hK13在50%的卵巢癌组织中似乎过表达。添加到牛奶或羊水中的活性酶的回收率为70–98%,但是添加到血清中的回收率则为<20%,这表明蛋白酶抑制剂可以快速隔离。在体液和组织提取物中,hK13以其游离形式(〜30 kDa)被发现。结论:这种hK13的免疫荧光测定法可用于检查hK13作为疾病生物标志物的价值,并进一步探讨其的生理和病理生物学作用人体疾病中的酶。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号